Company intelligence / Profile preview
NatureCell
Seoul, Seoul, South Koreaen.naturecell.co.kr ↗
- Ownership
- Private
- Employees
- ~77
- Development stage
- Other
01
Overview
NatureCell is the first Korean company to receive FDA Breakthrough Therapy Designation for its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, in the treatment of osteoarthritis; clinical trials have produced positive safety and efficacy data over a three-year follow-up period[2][3][6].
- Therapeutic areas
- Rheumatology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on NatureCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NatureCell.